|
|||
2011-04-27 07:05:00 CEST 2011-04-27 07:05:26 CEST REGULATED INFORMATION Okmetic Oyj - Interim report (Q1 and Q3)OKMETIC INTERIM REPORT 1 JANUARY - 31 MARCH 2011OKMETIC OYJ STOCK EXCHANGE RELEASE 27 APRIL 2011 AT 8.05 A.M. OKMETIC INTERIM REPORT 1 JANUARY - 31 MARCH 2011 Unless otherwise stated, figures in parenthesis refer to the corresponding period in the previous year. JANUARY-MARCH IN BRIEF: The net sales amounted to 22.1 (16.5) million euro, up 33.5%. Operating profit was 2.8 (0.8) million euro corresponding to 12.8% of net sales. Profit for the period was 2.7 (1.0) million euro. Profit for the period was improved by 0.7 million euro due to recognition of deferred tax assets relating to tax losses carried forward. Basic earnings per share for the period were 0.16 (0.06) euro. The net cash flow from operations amounted to -1.3 (2.4) million euro. PROJECTIONS FOR 2011 The net sales and operating profit for the first half of 2011 are estimated to clearly exceed the level of the corresponding period in 2010. Reaching these estimates means that the current positive market situation must not see any significant changes during the first half of the year. PRESIDENT KAI SEIKKU:"The first quarter saw growth in all product groups. The best results came from sensor wafers, the sales of which in euro increased by 47% compared to the corresponding period last year. Also technology sales mainly consisting of solar materials went very well between January-March. With semiconductor wafers, the growth was more moderate in consequence of the industry's seasonal variation. The net sales and operating profit exceeded the target level due to positive progress in February and March. Together with the prospects for the second quarter, this positive trend gave reason to adjust the estimate for the first half of the year during the period. The natural disaster in Japan in March did not have a significant effect on sales or result for the first quarter. It is still hard to estimate the potential long-term direct and indirect effects of the disaster on the electronics industry's value chain and on Okmetic's business. As a counterweight to the positive financial performance, the net cash flow from operations in January-March included items that significantly weakened the cash flow compared to the corresponding period last year. Along with the increase in the normal net working capital items, these included i.a. advance payments for the long-term supply agreement for polysilicon and bonus payments for personnel from the financial year 2010. For the financial year 2009, coinciding with the downturn in the semiconductor market, no bonuses were paid. In January, Okmetic invested in opening production bottlenecks by reclaiming ten crystal growing furnaces owned by the Norwegian company NorSun, which were already located at the Vantaa production plant. The 3.3 million euro investment is part of the company's growth strategy." KEY FIGURES 1,000 euro 1.1.- 1.1.- 1.1.- 1.1.- 31.3.11 31.3.10 31.12.10 31.12.09 Net sales 22,055 16,521 80,907 54,361 Operating profit before depreciation (EBITDA) 4,425 2,488 17,102 7,121 Operating profit 2,828 788 10,421 185 % of net sales 12.8 4.8 12.9 0.3 Profit/loss for the period 2,724 1,027 9,952 -513 Basic earnings per share, euro 0.16 0.06 0.60 -0.03 Net cash flow from operating activities -1,337 2,417 16,594 6,315 Net interest- bearing liabilities -12,379 -6,795 -18,047 -4,770 Equity ratio, % 78.9 76.3 76.6 78.9 Average number of personnel during the period 347 329 345 337 CHANGE IN ACCOUNTING POLICIES From the start of 2011 Okmetic has changed the place where changes in fair values of currency derivative contracts and their realised profits and losses are presented in the statement of comprehensive income. In line with the new policy, the changes in the fair values of currency derivative contracts and their realised profits and losses are presented with the financial income and expenses. Previously these items were presented with other operating income and expenses. The company's view is that the operating profit, thanks to the change, will provide better and more significant information regarding the development of the company's financial result and the factors contributing to it. A corresponding change has been made in all previous periods' figures presented in this interim report. Effect of the change in accounting policies on operating profit 1-3/ 4-6/ 7-9/ 10-12/ 2010 2010 2010 2010 2010 Operating profit, 1,000 euro New accounting policy 788 2,481 3,712 3,440 10,421 Old accounting policy 684 2,467 3,891 2,758 9,801 Operating profit, % of net sales New accounting policy 4.8 12.6 17.2 14.9 12.9 Old accounting policy 4.1 12.5 18.0 12.0 12.1 MARKETS Customer industries sensor, semiconductor, and solar cell industries Sensor industry In 2011, the sale value of sensor industry is estimated to grow 9 percent compared to the sale value of 2010 (7.1 billion US dollars). One of the fastest growing sectors is MEMS products for consumer applications such as microphones, gyroscopes and picoprojectors (IHS, ISuppli). Nowadays, silicon-on-insulator (SOI) technology is widely used in the manufacture of these next generation products, and the share of SOI technology is estimated to continue its growth. Okmetic is amongst the pioneering suppliers who provide products and services based on SOI technology to the sensor industry. Semiconductor industry The US dollar based growth estimate for the semiconductor industry's sales in 2011 is between 6 and 10 percent (Semiconductor Intelligence, ICInsights, Gartner, IHS, ISuppli). Every quarter of the year is expected to have a positive growth rate, and it is expected that the market will return to normal quarterly fluctuation in 2012 (Semiconductor Intelligence). The growth will be supported by some components' higher average price than estimated earlier. This is a result of the Japan's earthquake's effects on production. (IHS, Isuppli) Solar cell industry The growth of solar cell industry's demand has moderated after the exceptionally strong growth in 2010. Due to the rapidly growing production capacity, stock levels have risen throughout the industry's supply chain (Solarbuzz). The major European solar energy users, especially Germany and Italy, reduce feed-in tariffs in the middle of the on-going year, which increases the uncertainty related to the market development in the latter half of the year. Silicon wafer market According to the report published in February 2011 by SMG, the group of silicon wafer suppliers in SEMI, the volume of wafer shipments in the silicon wafer industry in 2010 soared up 40 percent compared to the shipment volumes in 2009 reaching a new record level. The accumulated net sales rose 45 percent to 9.7 billion US dollars from 6.7 billion US dollars in the previous year. Similar to semiconductor market, silicon wafer market is estimated to grow moderately in 2011. Okmetic's central customer areas in the silicon wafer market In line with its strategy, Okmetic seeks for special areas of the entire silicon wafer market that have greater growth rates than the market average and in which the company has special know-how. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS industry is Okmetic's central growth area. The MEMS market grows as the portable consumer products, automotive electronics, and industrial process control increase. In the semiconductor market, Okmetic's growth areas include discrete and power semiconductors. The growth areas of these markets are i.a. components used in the production of renewable energy, increasing automotive electronics, portable consumer products, developing applications of the medical and well-being industries as well as industrial process controlling. EVENTS AFTER THE INTERIM REPORT PERIOD Okmetic's board of directors has approved plans to increase the group's SOI wafer production capacity by extending the Vantaa plant. The around 30 million euro investment includes the plant extension and different kinds of production equipment. This investment, together with the on-going SOI equipment investments, more than triples the Vantaa plant's current SOI wafer production capacity. More information on the investment is given in the stock exchange release published earlier today. At the same time, the board of directors approved the company's revised long- term financial objectives. The company's aim is that the organic net sales grow a minimum of 10 percent annually and that the operating profit is over 10 percent of the net sales. The company's previous long-term financial objectives stated that the organic net sales grow a minimum of 6 percent annually and that the operating profit is over 10 percent of the net sales. At the same the company discarded other specifically defined long-term financial objectives such as a 50 percent equity ratio and consistent annual dividend distribution. SALES In January-March, Okmetic's net sales increased by 33.5 (11.3) percent from the previous year amounting to 22.1 (16.5) million euro. The growth of net sales was supported especially by good sensor industry demand. Okmetic succeeded to increase its market share in the product groups which are important to the company. Sales per customer area 1.1.- 1.1.- 1.1.- 1.1.- 31.3.11 31.3.10 31.12.10 31.12.09 Sensors 45% 42% 43% 41% Semiconductors 33% 42% 42% 31% Technology 22% 16% 15% 28% In January-March, the value of sensor wafer sales was 47 percent higher than in the corresponding period last year. The resumption of semiconductor industy's good economic trend had a positive influence on the semiconductor wafer sales. In January-March, the sale value of these wafers was 7 percent higher than in the corresponding period last year. In January-March, technology sales comprised mainly of solar crystal sales. Sales per market area 1.1.- 1.1.- 1.1.- 1.1.- 31.3.11 31.3.10 31.12.10 31.12.09 North America 37% 40% 43% 37% Europe 31% 29% 25% 33% Asia 32% 31% 32% 30% In the first quarter, sales per market area were distributed quite evenly. The proportion of Europe of the total net sales grew during the period under review. PROFITABILITY In January-March, Okmetic's operating profit was 2.8 (0.8) million euro. The operating profit accounted for 12.8 (4.8) percent of net sales. The profit for the period amounted to 2.7 (1.0) million euro. Profit for the period was improved by 0.7 million euro due to recognition of deferred tax assets relating to tax losses carried forward. Basic earnings per share were 0.16 (0.06) euro. FINANCING The company's financial situation is good. In January-March, the net cash flow from operations amounted to -1.3 (2.4) million euro. The cash flow from operations was weakened by 6.0 (0.3) million euro due to changes in working capital available to business operations. This figure includes normal changes in net working capital worth of 1.1 million euro. Other items are advance payments for the supply agreement for polysilicon, share reward scheme's withholdings, white-collar employees' bonuses for the financial year 2010 as well as currency derivative contracts' expenses. On 31 March 2011, the company's liabilities amounted to 1.0 (1.0) million euro. At the end of the period, cash and cash equivalents amounted to 10.4 (9.3) million euro. In addition to this, the company had 3.0 million euro worth of investments in fixed-income funds. On 31 March 2011, the company's cash and cash equivalents exceeded the interest-bearing liabilities by 12.4 million euro (on 31 March 2010, cash and cash equivalents were 6.8 million euro higher than interest-bearing liabilities). Return on equity amounted to 18.3 (8.4) percent. The company's equity ratio was 78.9 (76.3) percent. Equity per share was 3.63 (2.97) euro. INVESTMENTS In January-March, Okmetic's capital expenditure amounted to 3.9 (0.0) million euro. Okmetic used its call option in January to purchase the ten crystal growing furnaces owned by the Norwegian company NorSun, and located at the Vantaa production plant. The total amount of the investment was 3.3 million euro. As a result of the investment, Okmetic's own crystal growing capacity increased significantly. The acquired furnaces are meant to be used for the production of solar crystals, and in the future for the crystal growing required for the own production and contract manufacturing of silicon wafers. Okmetic thus secures sufficient production capacity for the needs of coming years. PRODUCT DEVELOPMENT In January-March, the company expensed 0.6 (0.5) million euro in long-term product development projects. Product development costs accounted for 2.7 (2.9) percent of net sales. Product development costs have not been capitalised. Product development has been allocated to sensor wafers and crystal growing that are important to Okmetic. PERSONNEL On average, Okmetic employed 347 (329) people in January-March. At the end of the period, 311 of the company's employees worked in Finland, 37 in the US, and three in Japan. OKMETIC'S CORPORATE GOVERNANCE Okmetic Oyj's annual general meeting, which was held on 7 April 2011, adopted the financial statements for 2010 and discharged the company's management from liability. It was decided that a dividend of 0.30 euro per share would be distributed for 2010. The dividend was paid on Tuesday 19 April 2011. The annual general meeting decided also, in accordance with the proposal of the board of directors, to authorise the board of directors to decide upon its discretion on the payment of an additional dividend, should the company's financial situation permit this. The additional dividend, including any number of separate decisions on dividend payment, may amount up to a maximum of 0.40 euro per share and 15,000,000 euro in total. Moreover, the general meeting approved the proposal of the board of directors to authorise the board of directors to decide on the repurchase and/or the acceptance as pledge of the company's own shares, transferring rights to the company's own shares, issuance of shares and issuance of special rights entitling to shares. It was decided that there would be five members on the company's board of directors. Mr. Tapani Järvinen, Mr. Hannu Martola, Mr. Pekka Salmi and Mr. Henri Österlund were re-elected as members of the board of directors until the end of the next annual general meeting, and Ms. Mervi Paulasto-Kröckel was elected as a new member. The board of directors elected Henri Österlund as its chairman and Tapani Järvinen as its vice chairman in its organisation meeting held immediately after the annual general meeting. Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor, with APA Mikko Nieminen having the principal responsibility. Authorisations given to the board of directors and other decisions of the annual general meeting have been notified in a stock exchange release published on 7 April 2011. BUSINESS RISKS IN THE NEAR FUTURE There have been no essential changes in the company's near future business risks and uncertainties. So far, the natural disaster in Japan has not known to have added business risks. It is still hard to estimate the potential long-term direct and indirect effects of the events in Japan on the electronics industry's value chain and on Okmetic's business. Other most significant factors causing uncertainty for Okmetic's business in the near future are related especially to the sensitivity of semiconductor wafer demand to economic fluctuations and to the rapid and strong changes in the market situation. The current strong demand may create excessive orders and stock in the market. Clearing this stock may decrease demand significantly. The company only has considerable pricing power with its own special products. The pricing of other wafers is mainly based on global market price. The most common trade currency in the field is the US dollar. The company's result is affected by US dollar's strong currency changes against the euro. The fact that Okmetic's main production facilities are located in the relatively expensive euro zone places cost pressure for the company. Other challenges include maintaining market leadership position in our special fields, together with meeting the demand gearing towards bigger wafer sizes. The company risks and uncertainty factors are dealt more profoundly in the company's annual report of 2010. SHARES AND SHAREHOLDERS On 31 March 2011, Okmetic Oyj's paid-up share capital, as entered in the Finnish trade register, was 11,821,250 euro. The number of shares was 17,287,500. The shares have no nominal value attached. Each share entitles its holder to one vote at general meeting. The company has one class of shares. SHARE PRICE DEVELOPMENT AND TRADING A total of 3.6 (2.8) million shares were traded between 1 January and 31 March 2011, representing 20.8 (16.3) percent of the weighted average of share total of 17.3 (17.0) million during the period. The lowest quotation of the reporting period was 5.30 (2.98) euro, and the highest 6.65 (3.51) euro, with the average being 5.90 (3.18) euro. The closing quotation for the period was 6.55 (3.41) euro. At the end of the period, the market capitalisation amounted to 113.2 (59.0) million euro. OWN SHARES On 16 February 2011, Okmetic's board of directors decided on a transfer of 125,390 own shares, held by the company, as a part of the company's share-based incentive scheme for the executive management group, of which the company has given a stock exchange release on 11 February 2010. All the shares were issued to the members of the executive management group in deviation from the shareholders' pre-emptive rights (directed share issue). The rewards of the share reward programme were paid on one hand in Okmetic shares and on the other hand in a monetary amount covering taxes. The directed share issue without payment was executed in full as there was no consideration related to the issue. The share issue did not affect the share capital of the company. At the end of the period, the company held a total of 77,854 shares, which is approximately 0.5 percent of Okmetic's all shares and votes. CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 MARCH 2011 (unaudited) ACCOUNTING POLICIES These interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting. In preparing these interim financial statements, Okmetic has followed the same accounting policies as in the financial statements for 2010 except for the effect of changes required by the adoption of the following new or revised standards and interpretations as of 1 January 2011: IAS 24 (revised), Related Party Disclosures IAS 32 (amendment), Financial Instruments: Presentation - Classification of Rights Issues IFRIC 19, Extinguishing Financial Liabilities with Equity Instruments IFRIC 14 (amendment), Prepayments of a Minimum Funding Requirement Improvements to IFRSs, May 2010 The adoption of the aforementioned standards and interpretations has not had an effect on the figures presented from the reporting period. From the start of 2011 Okmetic has changed the place where changes in fair values of currency derivative contracts and their realised profits and losses are presented in the statement of comprehensive income. In line with the new policy, the changes in the fair values of currency derivative contracts and their realised profits and losses are presented with the financial income and expenses. Previously these items were presented with other operating income and expenses. The company's view is that the operating profit, thanks to the change, will provide better and more significant information regarding the development of the company's financial result and the factors contributing to it. A corresponding change has been made in all previous periods' figures presented in this interim report. CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 1,000 euro 1 Jan- 1 Jan- 1 Jan- 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Net sales 22,055 16,521 80,907 Cost of sales -15,939 -13,826 -62,274 Gross profit 6,116 2,695 18,633 Other income and expenses -3,288 -1,907 -8,212 Operating profit 2,828 788 10,421 Financial income and expenses -532 130 -610 Profit before tax 2,296 918 9,811 Income tax 428 109 141 Profit for the period 2,724 1,027 9,952 Other comprehensive income: Translation differences -203 364 624 Total comprehensive income for the period 2,521 1,390 10,576 Profit for the period attributable to: Equity holders of the parent company 2,724 1,027 9,952 Total comprehensive income attributable to: Equity holders of the parent company 2,521 1,390 10,576 Basic earnings per share, euro 0.16 0.06 0.60 Diluted earnings per share, euro 0.16 0.06 0.58 CONDENSED CONSOLIDATED BALANCE SHEET 1,000 euro 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Assets Non-current assets Property, plant and equipment 32,065 31,847 29,069 Other receivables 4,251 3,568 2,441 Total non-current assets 36,316 35,414 31,510 Current assets Inventories 10,319 7,806 9,987 Receivables 17,461 12,586 15,674 Financial assets at fair value through profit or loss 3,013 - 5,004 Cash and cash equivalents 10,366 9,316 14,043 Total current assets 41,158 29,709 44,708 Total assets 77,475 65,123 76,217 Equity and liabilities Equity Equity attributable to equity holders of the parent company Share capital 11,821 11,821 11,821 Other equity 49,199 37,700 46,420 Total equity 61,021 49,522 58,242 Liabilities Non-current liabilities 1,526 3,668 1,245 Current liabilities 14,927 11,934 16,730 Total liabilities 16,454 15,602 17,976 Total equity and liabilities 77,475 65,123 76,217 CONDENSED CONSOLIDATED CASH FLOW STATEMENT 1,000 euro 1 Jan- 1 Jan- 1 Jan- 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Cash flows from operating activities: Profit before tax 2,296 918 9,811 Adjustments 2,735 1,675 6,795 Change in working capital -5,950 -263 210 Financial items -419 62 -279 Tax paid - 26 58 Net cash from operating activities -1,337 2,417 16,594 Cash flows from investing activities: Purchases of property, plant and equipment -3,908 -23 -2,173 Investments in fixed income funds 2,003 - -5,000 Net cash used in investing activities -1,905 -23 -7,173 Cash flows from financing activities: Repayments of long-term borrowings - - -1,500 Payments of finance lease liabilities - -17 -39 Share issue - 1,200 1,200 Repurchase of own shares - -1,810 -1,868 Dividends paid - - -834 Net cash used in financing activities - -627 -3,041 Increase(+) / decrease (-) in cash and cash equivalents -3,243 1,767 6,381 Exchange rate changes -434 242 355 Cash and cash equivalents at the beginning of the period 14,043 7,307 7,307 Cash and cash equivalents at the end of the period 10,366 9,316 14,043 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Equity attributable to equity holders of parent company Share Share Reserve Trans- Retained Total capital pre- for in- lation differ- earnings mium vested ences 1,000 euro unre- stricted equity Balance at 31 Dec, 2010 11,821 20,045 1,200 1,039 24,137 58,242 Profit for the period 2,724 2,724 Translation differences -203 -203 Total comprehen- sive income for the period -203 2,724 2,521 Share- based incentive scheme 258 258 Balance at 31 Mar, 2011 11,821 20,045 1,200 836 27,118 61,021 Balance at 31 Dec, 2009 11,821 20,045 - 415 16,461 48,742 Profit for the period 1,027 1,027 Translation differences 364 364 Total comprehen- sive income for the period 364 1,027 1,390 Share issue 1,200 1,200 Repurchase of own shares -1,810 -1,810 Balance at 31 Mar, 2010 11,821 20,045 1,200 778 15,677 49,522 CHANGES IN PROPERTY, PLANT AND EQUIPMENT 1,000 euro 1 Jan- 1 Jan- 1 Jan- 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Carrying amount at the beginning of the period 29,069 33,174 33,174 Additions 4,837 21 2,232 Disposals - - -74 Depreciation -1,597 -1,699 -6,681 Exchange differences -245 351 419 Carrying amount at the end of the period 32,065 31,847 29,069 COMMITMENTS AND CONTINGENCIES 1,000 euro 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Loans, secured with collaterals 1,000 1,000 1,000 Collaterals 8,073 8,073 8,073 Off-balance sheet lease commitments 206 121 245 Capital commitments 4,226 318 2,190 Nominal values of derivative contracts Currency options, call 9,699 - 15,244 Currency options, put 5,146 - 18,034 Currency forward agreements - 707 - Electricity derivatives 1,703 2,245 2,038 Interest rate swaps - 6,429 - Fair values of derivative contracts Currency options, call 226 - 184 Currency options, put -9 - -595 Currency forward agreements - -35 - Electricity derivatives 210 -302 544 Interest rate swaps - -162 - The contract price of the derivatives has been used as the nominal value of the underlying asset. Derivative contracts are for hedging. KEY FIGURES SHOWING FINANCIAL PERFORMANCE 1,000 euro 1 Jan- 1 Jan- 1 Jan- 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Net sales 22,055 16,521 80,907 Change in net sales compared to the previous year's period, % 33.5 11.3 48.8 Export and foreign operations share of net sales, % 94.6 95.6 95.8 Operating profit before depreciation (EBITDA) 4,425 2,488 17,102 % of net sales 20.1 15.1 21.1 Operating profit 2,828 788 10,421 % of net sales 12.8 4.8 12.9 Profit before tax 2,296 918 9,811 % of net sales 10.4 5.6 12.1 Return on equity, % 18.3 8.4 18.6 Return on investment, % 15.1 8.3 18.2 Non-interest-bearing liabilities 15,454 13,081 16,976 Net interest-bearing liabilities -12,379 -6,795 -18,047 Net gearing ratio, % -20.3 -13.7 -31.0 Equity ratio, % 78.9 76.3 76.6 Capital expenditure 4,837 21 2,232 % of net sales 21.9 0.1 2.8 Depreciation 1,597 1,699 6,681 Research and development expenditure 1) 595 487 2,110 % of net sales 2.7 2.9 2.6 Average number of personnel during the period 347 329 345 Personnel at the end of the period 351 329 342 1) Research and development expenditure has been presented in gross figures and only long-term projects based on research program have been taken into account. KEY FIGURES PER SHARE Euro 31 Mar, 31 Mar, 31 Dec, 2011 2010 2010 Basic earnings per share 0.16 0.06 0.60 Diluted earnings per share 0.16 0.06 0.58 Equity per share 3.63 2.97 3.49 Dividend per share - - 0.30 Dividends/earnings, % - - 51.7 Effective dividend yield, % - - 5.7 Price/earnings(P/E) - - 8.9 Share performance(1 Jan-) Average trading price 5.90 3.18 4.22 Lowest trading price 5.30 2.98 2.98 Highest trading price 6.65 3.51 5.70 Trading price at the end of the period 6.55 3.41 5.29 Market capitalisation at the end of the period, 1,000 euro 113,233 58,950 91,451 Trading volume (1 Jan-) Trading volume, transactions, 1,000 pcs 3,601 2,774 14,009 In relation to weighted average number of shares, % 20.8 16.3 81.4 Trading volume, 1,000 euro 21,242 8,829 59,124 The weighted average number of shares during the period under review adjusted by the share issue, 1,000 pcs 17,288 17,012 17,220 The number of shares at the end of the period adjusted by the share issue, 1,000 pcs 17,288 17,288 17,288 When calculating earnings per share (EPS) and equity, Okmetic's own shares in its possession and Okmetic's shares owned by Okmetic Management Oy are deducted from the amount of shares. QUARTERLY KEY FIGURES 1,000 euro 10-12/ 7-9/ 4-6/ 1-3/ 2011 2011 2011 2011 Net sales 22,055 Compared to previous quarter, % -4.4 Compared to corresponding period last year, % 33.5 Operating profit 2,828 % of net sales 12.8 Profit before tax 2,296 % of net sales 10.4 Net cash flow generated from: Operating activities -1,337 Investing activities -1,905 Financing activities - Increase/decrease in cash and cash equivalents -3,243 Personnel at the end of the period 351 1,000 euro 10-12/ 7-9/ 4-6/ 1-3/ 2010 2010 2010 2010 Net sales 23,072 21,626 19,688 16,521 Compared to previous quarter, % 6.7 9.8 19.2 19.6 Compared to corresponding period last year, % 67.0 77.7 45.4 11.3 Operating profit 3,440 3,712 2,481 788 % of net sales 14.9 17.2 12.6 4.8 Profit before tax 2,972 2,934 2,987 918 % of net sales 12.9 13.6 15.2 5.6 Net cash flow generated from: Operating activities 6,730 5,573 1,874 2,417 Investing activities -6,536 -547 -66 -23 Financing activities -3 -5 -2,406 -627 Increase/decrease in cash and cash equivalents 191 5,021 -599 1,767 Personnel at the end of the period 342 340 373 329 MAJOR SHAREHOLDERS ON 31 MARCH 2011 Shares, Share, pcs % Ilmarinen Mutual Pension Insurance Company 1,651,626 9.6 Mandatum Life Insurance Company 800,000 4.6 The State Pension Fund 600,000 3.5 Veritas Pension Insurance Company 492,000 2.9 Varma Mutual Pension Insurance Company 477,175 2.8 Okmetic Management Oy 400,000 2.3 Etra-Invest Oy Ab 400,000 2.3 Sijoitusrahasto Taaleritehdas Arvo Markka Osake 375,100 2.2 Nordea Nordic Small Cap Fund 370,660 2.1 Aktia Secura Fund 361,681 2.1 Kaleva Mutual Insurance Company 217,700 1.3 Mutual Fund Evli Finnish Equity 212,700 1.2 Sijoitusrahasto Aktia Capital 181,512 1.1 Finlandia Suomi SR 120,000 0.7 OP-Finland Small Firms Fund 112,700 0.7 SR Arvo Finland Value 110,611 0.6 Virtanen Yhtiöt Oy 100,986 0.6 Okmetic Oyj 77,854 0.5 EQ Pikkujättiläiset / EQ Rahastoyhtiö 76,003 0.4 Handelsbanken Finnish shares Fund 75,000 0.4 Nominee registered shares 2,818,343 16.3 Others 7,255,849 42.0 Total 17,287,500 100.0 DEFINITIONS OF KEY FINANCIAL FIGURES Operating profit before depreciation = Operating profit + depreciation (EBITDA) Return on equity (ROE), % = Profit/loss for the period from continuing operations x 100/ ------------------------------------------ Equity(Average for the period) Return on investment (ROI), % = (Profit/loss before tax + interest and other financial expenses) x 100/ ------------------------------------------ Balance sheet total - non-interest bearing liabilities(average for the period) Equity ratio, % = Equity x 100/ ------------------------------------------ Balance sheet total - advances received Net interest-bearing liabilities = Interest-bearing liabilities - cash and cash equivalents Net gearing ratio, % = (Interest-bearing liabilities - cash and cash equivalents) x 100/ ------------------------------------------ Equity Earnings per share = Profit/loss for the period attributable to equity holders of the parent company/ ------------------------------------------ Adjusted weighted average number of shares in issue during the period Equity per share = Equity attributable to equity holders of the parent company/ ------------------------------------------ Adjusted number of shares at the end of the period Dividend per share = Dividend for the period/ ------------------------------------------ Adjusted number of shares at the end of the period Effective dividend yield, % = Dividend per share x 100/ ------------------------------------------ Trading price at the end of the period Price/earnings ratio (P/E) = Last adjusted trading price at the end of the period/ ------------------------------------------ Earnings per share Average trading price = Total traded amount in euro/ ------------------------------------------ Adjusted number of shares traded during the period Market capitalisation at the end of = Number of shares at the end of the period the period x trading price at the end of the period Trading volume = Number of shares traded during the period/ ------------------------------------------ Weighted average number of shares during the period All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure. The figures are unaudited. The future estimates and forecasts in this interim report are based on company management's current knowledge. Actual events and results may differ from the estimates presented here. PRESS CONFERENCE A press conference for the media and analysts will be held on Wednesday, 27 April 2011 at 9.30 a.m. at the World Trade Center, Aleksanterinkatu 17, second floor, Helsinki. In the conference, Okmetic's President Kai Seikku will present the group's development in January-March 2011 and prospects for 2011. We ask participants to kindly give advance notice of their attendance by email to communications@okmetic.com or by telephone to +358 9 5028 0406/Marika Mäntymaa. OKMETIC OYJ Board of directors For further information, please contact: President Kai Seikku, Okmetic Oyj, tel. +358 400 200 288, email: kai.seikku@okmetic.com Senior Vice President, Finance, IT, and Communications Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286, email: juha.jaatinen@okmetic.com Distribution: NASDAQ OMX Helsinki Principal media www.okmetic.com OKMETIC IN BRIEF Take it higher Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise to the solar cell industry. Okmetic provides its customers with solutions that boost their competitiveness and profitability. Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process. Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com. [HUG#1509211] |
|||
|